Japan Tissue Engineering Co., Ltd. (JP:7774) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Japan Tissue Engineering Co., Ltd. has announced the National Health Insurance listing of its innovative treatment for vitiligo, ‘JACEMIN’, starting October 1, 2024. ‘JACEMIN’ is a regenerative medical product that transplants autologous cultured epidermis, maintaining melanocytes to restore pigmentation in patients. This low-invasive treatment is expected to significantly improve the quality of life for vitiligo patients in Japan.
For further insights into JP:7774 stock, check out TipRanks’ Stock Analysis page.